Goldman Sachs: Maintains Alibaba Health(00241.HK) "neutral" rating, lowers target price to 4.2 Hong Kong dollars.

According to the Securities Times APP, Goldman Sachs released a research report stating that Alibaba Health (00241.HK) will have mixed performance in the second half of the 2026 fiscal year ending in late March. The bank maintains a "neutral" rating on the company, lowering its 12-month target price from 4.8 Hong Kong dollars to 4.2 Hong Kong dollars, based on a forecasted average price-earnings ratio of 28 times for the 2027 to 2028 fiscal years. The report believes that revenue growth will be mainly driven by drugs (especially prescription drugs and innovative products), but intense competition will result in slower growth compared to JD Health (06618.HK). It is expected that Alibaba Health's revenue will increase by 13% year-on-year by the end of the 2027 fiscal year ending in March next year, while JD Health's revenue growth in 2026 is expected to reach 18%.